We are just beginning to learn about the immune reconstitution attained when HIV-infected patients attain substantial viral suppression with highly active antiretroviral therapy. For the first few months of therapy, patients have…

Although a complete discussion of the therapy for the pregnant HIV-infected patient is beyond the scope of this section, it is worth highlighting several important issues. First, it is generally accepted…

The substantial recent developments in AIDS therapy and in our ability to monitor viral dynamics have led to a major shift in the thinking about HIV therapy. Several panels…

Starting in the early 1990s, a number of structurally unrelated non-nucleoside compounds were discovered to be potent non-competitive inhibitors of HIV reverse transcriptase. These compounds share the property of having highly specific activity…

The second enzyme of HIV to be successfully targeted was the viral aspartyl protease. HIV produces the structural proteins of the viral core, as well as the integral viral enzymes, as Gag and Gag-Pol polyproteins…

Before going on to discuss specific recommendations for therapy, it is of value to review the drugs that are presently available for the treatment of HIV. As noted earlier,…

For some time after the discovery of HIV, the technology for measuring virus was relatively insensitive and it appeared that the degree of T-cell destruction was much greater…

Since the identification of the acquired immunodeficiency syndrome (AIDS) as a new entity in 1981, dramatic changes have occurred in therapy for this…